Phizer (PFE) Will Perform Despite Difficult Second Half - Jefferies

August 9, 2012 1:25 PM EDT Send to a Friend
Get Alerts PFE Hot Sheet
Price: $29.30 +1.81%

Rating Summary:
    13 Buy, 7 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 13 | Down: 28 | New: 14
Trade PFE Now!
Jefferies reiterated their Buy rating on Pfizer (NYSE: PFE) and upped their price target to $26.00 (from $25.00).

“Q2'12 looked almost as tough as it can get,” said analyst Jeffrey Holford, “yet Pfizer delivered a strong beat at the bottom line driven by exceptional cost control and aggressive share repurchases. H2'12 will be tougher still as the worst comps on generics and FX are yet to come.”

However, Holford believes that the failure of bapineuzumab and the delays to Eliquis and tofacitinib are already discounted into expectations, and the shares can continue to perform well from here.

For an analyst ratings summary and ratings history on Pfizer click here. For more ratings news on Pfizer click here.

Shares of Pfizer closed at $23.83 yesterday, with a 52 week range of $16.63-$24.49.


Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here



You May Also Be Interested In


Related Categories

Analyst Comments, Analyst EPS View, Analyst PT Change

Related Entities

Jefferies & Co

Add Your Comment